Otic Pharma Ltd develops therapeutic products for ear, nose, and throat (ENT) disorders. The companys leading investigational drug, FoamOtic Externa, which is currently being prepared for a Phase III clinical trial, is a foam-based version of the industrys most commonly used, non-ototoxic antibiotic, ciprofloxacin.
Based on the companys proprietary FoamOtic platform, FoamOtic Externa enables sustained drug exposure, fewer administrations, and lower doses for treatment of acute otitis externa (AOE, or "swimmer's ear"). This steroid-free product is easy to apply, with no need to tilt the head or lie on one's side to ensure that the medication remains in the ear. This makes administration more convenient, especially for children, and thus can improve compliance and safety.
Other pipeline products based on the FoamOtic platform in development include FoamOtic Sinus for chronic sinusitis, Foam-O-Vet for otitis externa in dogs, and FoamOtic Media for the treatment of otitis media.